Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGTXNASDAQ:CMNDNASDAQ:GOVXNASDAQ:SNYR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGTXCognition Therapeutics$0.25+2.1%$0.37$0.22▼$2.54$15.41M12.61 million shs559,308 shsCMNDClearmind Medicine$0.97+0.6%$1.00$0.85▼$2.30$4.12M0.89873,968 shs53,985 shsGOVXGeoVax Labs$1.07+0.9%$1.01$0.73▼$11.18$16.26M3.47523,788 shs147,892 shsSNYRSynergy CHC Corp. (Uplisting)$1.81-2.2%$2.16$0.12▼$10.00$16.64MN/A684,330 shs28,502 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGTXCognition Therapeutics-5.76%-23.47%-41.51%-46.85%-88.93%CMNDClearmind Medicine-0.94%-3.91%-6.71%-21.24%-15.71%GOVXGeoVax Labs-1.85%+8.17%+3.92%-26.39%-34.97%SNYRSynergy CHC Corp. (Uplisting)+3.93%-11.90%-3.65%-51.32%+184,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCGTXCognition Therapeutics2.8719 of 5 stars3.53.00.00.01.62.51.3CMNDClearmind Medicine0.9678 of 5 stars0.04.00.00.03.01.70.0GOVXGeoVax Labs3.4739 of 5 stars3.64.00.00.03.31.71.3SNYRSynergy CHC Corp. (Uplisting)3.228 of 5 stars3.80.00.00.02.61.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGTXCognition Therapeutics 3.00Buy$5.632,162.67% UpsideCMNDClearmind Medicine 0.00N/AN/AN/AGOVXGeoVax Labs 3.29Buy$11.10937.38% UpsideSNYRSynergy CHC Corp. (Uplisting) 3.50Strong Buy$10.00452.49% UpsideCurrent Analyst Ratings BreakdownLatest CMND, GOVX, SNYR, and CGTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025CGTXCognition TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.00 ➝ $3.005/8/2025CGTXCognition TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $4.005/2/2025GOVXGeoVax LabsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $9.004/16/2025GOVXGeoVax LabsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.004/15/2025GOVXGeoVax LabsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $8.504/10/2025GOVXGeoVax LabsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.003/28/2025GOVXGeoVax LabsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.003/24/2025CGTXCognition TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $5.003/21/2025CGTXCognition TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $8.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGTXCognition TherapeuticsN/AN/AN/AN/A$0.76 per shareN/ACMNDClearmind MedicineN/AN/AN/AN/A$0.73 per shareN/AGOVXGeoVax Labs$5.59M2.91N/AN/A$3.24 per share0.33SNYRSynergy CHC Corp. (Uplisting)$33.59M0.50N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGTXCognition Therapeutics-$25.79M-$0.74N/AN/AN/AN/A-150.93%-100.82%8/14/2025 (Estimated)CMNDClearmind Medicine-$5.26M-$1.22N/A∞N/AN/A-129.21%-61.15%6/12/2025 (Estimated)GOVXGeoVax Labs-$25.97M-$3.65N/AN/AN/AN/A-809.87%-349.34%8/5/2025 (Estimated)SNYRSynergy CHC Corp. (Uplisting)N/AN/A0.003.07N/AN/AN/AN/AN/ALatest CMND, GOVX, SNYR, and CGTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025SNYRSynergy CHC Corp. (Uplisting)$0.07$0.10+$0.03$0.10$9.03 million$8.17 million5/6/2025Q1 2025CGTXCognition Therapeutics-$0.12-$0.14-$0.02-$0.14N/AN/A5/1/2025Q1 2025GOVXGeoVax Labs-$0.59-$0.45+$0.14-$0.45$0.75 million$1.64 million3/31/2025Q4 2024SNYRSynergy CHC Corp. (Uplisting)$0.10$0.01-$0.09$0.01$10.55 million$10.30 million3/27/2025Q4 2024GOVXGeoVax Labs-$0.79-$0.30+$0.49-$0.30$2.38 million$3.00 million3/20/2025Q4 2024CGTXCognition Therapeutics-$0.16-$0.17-$0.01-$0.17N/AN/A3/13/2025Q1 2025CMNDClearmind MedicineN/A-$0.24N/A-$0.24N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCGTXCognition TherapeuticsN/AN/AN/AN/AN/ACMNDClearmind MedicineN/AN/AN/AN/AN/AGOVXGeoVax LabsN/AN/AN/AN/AN/ASNYRSynergy CHC Corp. (Uplisting)N/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGTXCognition TherapeuticsN/A2.112.11CMNDClearmind Medicine0.011.721.72GOVXGeoVax LabsN/A4.174.17SNYRSynergy CHC Corp. (Uplisting)N/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGTXCognition Therapeutics43.35%CMNDClearmind Medicine96.05%GOVXGeoVax Labs6.09%SNYRSynergy CHC Corp. (Uplisting)N/AInsider OwnershipCompanyInsider OwnershipCGTXCognition Therapeutics20.75%CMNDClearmind MedicineN/AGOVXGeoVax Labs1.20%SNYRSynergy CHC Corp. (Uplisting)N/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGTXCognition Therapeutics2061.99 million32.93 millionNot OptionableCMNDClearmind MedicineN/A4.27 millionN/ANot OptionableGOVXGeoVax Labs1015.19 million8.90 millionNot OptionableSNYRSynergy CHC Corp. (Uplisting)409.19 millionN/AN/ACMND, GOVX, SNYR, and CGTX HeadlinesRecent News About These CompaniesRoth Capital Has Pessimistic View of SNYR FY2025 EarningsMay 23, 2025 | americanbankingnews.comSynergy CHC Corp. (Uplisting) (NASDAQ:SNYR) CEO Jack Ross Buys 5,000 SharesMay 22, 2025 | insidertrades.comRoth Capital Issues Negative Outlook for SNYR EarningsMay 22, 2025 | americanbankingnews.comSynergy CHC Corp. Announces First Quarter 2025 Earnings and Conference Call InformationMay 1, 2025 | globenewswire.comSynergy CHC Stock Short Interest Report | NASDAQ:SNYR | BenzingaApril 17, 2025 | benzinga.comSynergy CHC Reports its Eighth Consecutive Quarter of Profitability and its Fourth Quarter and Full Year 2024 Financial ResultsMarch 31, 2025 | markets.businessinsider.comSynergy CHC Corp. Announces Fourth Quarter and Full Year 2024 Earnings and Conference Call InformationMarch 21, 2025 | markets.businessinsider.comRoth MKM Initiates Coverage of Synergy CHC (SNYR) with Buy RecommendationJanuary 22, 2025 | msn.comSynergy CHC Announces 7th Quarter of ProfitabilityDecember 7, 2024 | markets.businessinsider.comSynergy CHC Corp. (Uplisting) (NASDAQ:SNYR) CEO Purchases $2,700,000.00 in StockOctober 25, 2024 | insidertrades.comSynergy CHC Corp. Announces Closing of Initial Public OfferingOctober 24, 2024 | globenewswire.comSynergy CHC Corp. Prices $10.35 Million Initial Public OfferingOctober 22, 2024 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCMND, GOVX, SNYR, and CGTX Company DescriptionsCognition Therapeutics NASDAQ:CGTX$0.25 +0.01 (+2.22%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.Clearmind Medicine NASDAQ:CMND$0.94 -0.02 (-1.65%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; and with Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.GeoVax Labs NASDAQ:GOVX$1.07 +0.01 (+0.94%) As of 04:00 PM EasternGeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.Synergy CHC Corp. (Uplisting) NASDAQ:SNYR$1.81 -0.04 (-2.16%) As of 03:59 PM EasternSynergy CHC Corp. engages in the marketing and distribution of branded health and wellness products. The company was founded on December 29, 2010 and is headquartered in Westbrook, ME. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Intel's Loss Is Broadcom's Gain as AVGO Dominates Networking Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
